The FDA approved a wearable tumor-treating fields (TTFields) device (Optune Lua) for concurrent use with a PD-1/PD-L1 ...

Non-Small Cell Lung Cancer (NSCLC) Lung cancer is the most common cause of cancer-related death worldwide1, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers.

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...

Panelists discuss how biomarker testing is currently utilized in the management of patients with small cell lung cancer (SCLC), including its timing within the treatment journey, while also exploring ...

In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...

The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...

Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...

A significant weapon in the fight against lung cancer may be going to waste, as a survey revealed most Americans aren’t aware ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...

As immunotherapy makes breakthrough progress in the treatment of small cell lung cancer (SCLC), predicting treatment outcomes has become a focal point in clinical practice. Immunotherapy combined with ...

The work presented will be of interest to cancer biologists and more broadly to those interested in NSCLC translational studies. Non-small cell lung cancer (NSCLC) is the most common subtype of lung ...